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Background
The yeast Zygosaccharomyces bailii belongs to the so-called
group of non-conventional yeasts, poorly studied in the
past. For this reason, up to now there is no deep knowl-
edge regarding its physiology, genetics and molecular
biology, and its genetic manipulation is not easy. Only
recently this yeast attracted the attention of the scientific
community due to its characteristics of stress resistance,
particularly to acidic environments. Our group is working
on the construction and improvement of molecular tools
for an exploitation of Z. bailii as a new host system for bio-
technological applications.
Results
In spite of the good results already obtained for the pro-
duction and secretion of different proteins, a great limit
was represented by the lack of an auxotrophic mutant and
of a reproducible protocol for targeted gene deletion in
this yeast. Here we show the strategy used to obtain the
first Z. bailii auxotrophic mutant (Zbleu2 strain) and the
consequent exploitation of said mutant for heterologous
protein production and for metabolic engineering appli-
cations. The data obtained with the new strain showed a
great improvement of production, mainly related to
higher plasmid stability, if compared with the wild type
strain transformed with similar plasmid but selecting for
an antibiotic resistance. In addition, and once more
exploiting the leu2 auxotrophy, we are developing a strat-
egy for high copy number replication of an heterologous
gene of interest.
Conclusion
According to our knowledge, this is the first example of an
auxotrophic Z. bailii strain exploited for recombinant pro-
ductions. It represents a small but necessary step to
develop this host for biotechnological applications, that
already resulted in significant improvement in the pro-
ductions of interest.
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